Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma

Zhang, Yang; Zheng, Deyou; Li, Yuan; Pan, Yunjian; Sun, Yihua; Chen, Haiquan

doi:10.21037/jtd.2017.10.43

Cited by 15 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 39 ] Both can be found in the peripheral-type squamous cell carcinoma (P-SqCC) and pneumonic-type lung adenocarcinoma (P-ADC). [ 8 ] If patients in specific CT features (pleural tag and air bronchogram) with first tyrosine kinase inhibitors (TKIs) failure in peripheral location, they are more likely to have a recurrence in T790M status when rebiopsy. [ 40 ] There are other some specific CT features in first-line TKIs resistance, including vascular convergence, pleural tag, and bronchogram.…”

Section: Bronchus/central and Clinicopathologic Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Primary tumor location in lung cancer: the evaluation and administration

Xie

Tang

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

Lung cancer continues to be the leading cause of cancer-related death in the world, which is classically subgrouped into two major histological types: Non-small cell lung cancer (NSCLC) (85% of patients) and small-cell lung cancer (SCLC) (15%). Tumor location has been reported to be associated with the prognosis of various solid tumors. Several types of cancer often occur in a specific region and are more prone to spread to predilection locations, including colorectal cancer, prostate cancer, gastric cancer, ovarian cancer, cervical cancer, bladder cancer, lung tumor, and so on. Besides, tumor location is also considered as a risk factor for lung neoplasm with chronic obstructive pulmonary disease/emphysema. Additionally, the primary lung cancer location is associated with specific lymph node metastasis. And the recent analysis has shown that the primary location may affect metastasis pattern in metastatic NSCLC based on a large population. Numerous studies have enrolled the “location” factor in the risk model. Anatomy location and lobe-specific location are both important in prognosis. Therefore, it is important for us to clarify the characteristics about tumor location according to various definitions. However, the inconsistent definitions about tumor location among different articles are controversial. It is also a significant guidance in multimode therapy in the present time. In this review, we mainly aim to provide a new insight about tumor location, including anatomy, clinicopathology, and prognosis in patients with lung neoplasm.

show abstract

Section: Bronchus/central and Clinicopathologic Featuresmentioning

confidence: 99%

“…[ 41 ] PD-L1 expression was not only related to upper lobes but also associated with central locations. [ 41 ] Zhang et al [ 8 ] showed that central lung SCC has a higher frequency expression of TP63. Ki-67 immunostaining is considered to be an indicator of cellular proliferation.…”

Section: Bronchus/central and Clinicopathologic Featuresmentioning

confidence: 99%

Primary tumor location in lung cancer: the evaluation and administration

Xie

Tang

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…That none of 296 analyzed squamous cell carcinomas from other organs of origin were Napsin A positive further emphasizes that this protein is virtually absent in cells with squamous differentiation. It is of note that other investigators have reported Napsin A positivity in 0–10% of pulmonary squamous cell carcinomas in studies analyzing 14–569 tumors [ 16 , 18 , 22 , 24 , 46 – 48 , 50 , 52 , 57 – 59 , 61 – 65 , 67 – 69 ]. One possible reason for a perceived Napsin A positivity in squamous cell carcinomas that we and others encountered is entrapped normal lung tissue with Napsin A positive hyperplastic pneumocytes or Napsin A positive intra-alveolar macrophages between cancer cells [ 3 ].…”

Section: Discussionmentioning

confidence: 92%

“…More than 70 studies have previously analyzed Napsin A expression in tumors by IHC. The studies showed a wide range of Napsin A positivity for each tumor entity, for example, published Napsin A positivity rates ranged from 0% to 100% in adenocarcinoma of the lung [ 11 , 13 , 16 , 18 , 20 , 22 , 24 , 43 – 66 ], 0%–48% in papillary thyroid carcinoma [ 11 , 16 , 18 , 19 , 24 ], 0%–52% in clear cell renal cell carcinoma [ 6 , 13 , 15 – 19 , 22 , 24 ], 0%–17% in small cell carcinoma of the lung [ 13 , 22 , 50 , 61 , 63 ], 0–10% in squamous cell carcinoma of the lung [ 16 , 18 , 22 , 24 , 46 – 48 , 50 , 52 , 57 – 59 , 61 – 65 , 67 – 69 ], 69–100% in clear cell adenocarcinoma of the ovary [ 7 , 19 , 25 , 27 – 32 , 34 ], 72%–97% in papillary renal cell carcinoma [ 6 , 16 – 18 , 20 – 22 ] and 67%–89% in clear cell adenocarcinoma of the endometrium [ 7 , 30 , 70 , 71 ]. The analysis of a large number of different tumor entities under highly standardized conditions enabled us to clarify the relative importance of Napsin A expression across tumor entities and to generate a ranking list according to the expected rate of Napsin A positivity.…”

Section: Discussionmentioning

confidence: 99%

Napsin A Expression in Human Tumors and Normal Tissues

Weidemann

Böhle

Contreras³

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Background: Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.Methods: To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.Results: Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (p ≤ 0.03).Conclusion: This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.

show abstract

“…The majority of LSQCC are centrally located (c-LSQCC); a minority of these tumors is located in the peripheral lung (p-LSQCC). Interestingly, p-LSQCC have more mutations of EGFR than c-LSQCC (6.2% vs. 2.2%); furthermore, p-LSQCCs have the tendency to higher frequency of PIK3CA, KRAS and HER2 mutations than c-LSQCC (4.8% vs. 2.2%; 3.4% vs. 1.5%; 1.4% vs. 0%) [ 40 ].…”

Section: Genetic Abnormalities Of Lsqccmentioning

confidence: 99%

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells

Testa

Castelli

Pelosi

2018

Cancers

290

267

View full text Add to dashboard Cite

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (15%) (SCLC). The 5-year survival rate for NSCLC patients remains very low (about 16% at 5 years). The two predominant NSCLC histological phenotypes are adenocarcinoma (ADC) and squamous cell carcinoma (LSQCC). ADCs display several recurrent genetic alterations, including: KRAS, BRAF and EGFR mutations; recurrent mutations and amplifications of several oncogenes, including ERBB2, MET, FGFR1 and FGFR2; fusion oncogenes involving ALK, ROS1, Neuregulin1 (NRG1) and RET. In LSQCC recurrent mutations of TP53, FGFR1, FGFR2, FGFR3, DDR2 and genes of the PI3K pathway have been detected, quantitative gene abnormalities of PTEN and CDKN2A. Developments in the characterization of lung cancer molecular abnormalities provided a strong rationale for new therapeutic options and for understanding the mechanisms of drug resistance. However, the complexity of lung cancer genomes is particularly high, as shown by deep-sequencing studies supporting the heterogeneity of lung tumors at cellular level, with sub-clones exhibiting different combinations of mutations. Molecular studies performed on lung tumors during treatment have shown the phenomenon of clonal evolution, thus supporting the occurrence of a temporal tumor heterogeneity.

show abstract

Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma

Cited by 15 publications

References 16 publications

Primary tumor location in lung cancer: the evaluation and administration

Primary tumor location in lung cancer: the evaluation and administration

Napsin A Expression in Human Tumors and Normal Tissues

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells

Contact Info

Product

Resources

About